Company profile
Vivani Medical, Inc.
NASDAQ: VANI · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
33DFH 36DQ 34GM 9SS 56
v0.1 · 65/100 weight · provisional
↑ market scale, listing tenure · ↓ 3-yr revenue growth, growth stability
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$26.6M
Employees
42
as of 2026-08-18
Market cap
$118.6M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$26.6M-$26.6M2025
Operating income-$27.6M-$27.6M2025
Total assets$39.4M$39.4M2025
Liabilities$23.7M$23.7M2025
Equity$15.7M$15.7M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY18
FY19
FY19
FY19
FY19
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Vivani Medical, Inc.’s revenue?
Vivani Medical, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Spruce Biosciences, Inc.40DAardvark Therapeutics, Inc. Common Stock40DHelix BioPharma Corp.——Fractyl Health, Inc.28DParabilis Medicines, Inc.——Revium Recovery Inc.——Neighbors
Alameda →Key facts
CEOAdam Mendelsohn
SectorHealthcare
IndustryBiotechnology
HeadquartersAlameda, CA
ExchangeNASDAQ: VANI
Employees42
IPO date2014-11-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.